Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-0520 gel in prevention of taxanes-induced peripheral neuropathy
2025-521674-33-00Phase 2Authorised
- Sponsor
- Tarian Pharma
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of brimonidine in taxane-induced peripheral neuropathy (TIPN), sponsored by Tarian Pharma. Primary endpoint: Incidence of Adverse Events, Adverse Events of Special Interest and Serious Adverse Events. Planned start Jun 2025; status: authorised.
02
Drugs
brimonidine
03
Conditions
taxane-induced peripheral neuropathy (TIPN)
Beyond the preview
Go deeper on 2025-521674-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521674-33-00.